Receptor Grade IGF-1 LR3 (1mg)

Receptor Grade IGF-1 LR3 Peptide

Between 1940 and 1950, the growth hormone somatotropin was identified and researched. It was tentatively suggested that this hormone might enhance sulfate uptake in normal control rat serum, implying an increase in amino acid uptake or synthesis. However, this connection was not definitively established. This so-called "sulfate factor" was subsequently isolated from the rat serum and named "somatomedin." Concurrently, an independent study explored the components responsible for producing insulin-like activity. It was hypothesized during this investigation that these components might be "somatomedins," leading to the designation of these compounds as "insulin-like growth factors."⁽¹⁾

Further explorations into the insulin-like growth factors involved gene-targeting approaches to potentially enhance their bioavailability and potency. During these studies, a variant called Receptor Grade IGF-1 LR3 was developed. This variant included an additional arginine residue and featured an elongated structure at the N-terminal (by 13 amino acids), resulting in a protein composed of 83 amino acids, compared to the 70 amino acids found in natural IGF-1.⁽¹⁾

Receptor Grade IGF-1 LR3 peptide, a polypeptide amino acid also known as Long arginine 3 IGF-1, or LR3-IGF-1, has been suggested to exhibit potential action similar to Insulin-like Growth factor-1, or IGF-1.⁽²⁾ IGF-1 is a naturally produced protein comprised of 70 amino acids. Structurally similar to insulin, this Receptor Grade IGF-1 LR3 has the potential primarily to regulate cell tissue and development. Several synthetic variations of IGF-1, such as recombinant IGF-1 (rhIGF-1), were developed to mimic the natural protein identically and stimulate similar actions as IGF-1. Another example is Receptor Grade IGF-1 LR3, which researchers speculate exhibits an increased affinity and anabolic potential while binding less to IGF-1 binding proteins (IGF-1BPs). This variant has been developed particularly for evaluation in cell growth studies. Moreover, the designation of Receptor Grade refers to the purity of the material, which is considered higher than Media Grade IGF-1 LR3.

Structurally, IGF-1 LR3 contains an extended N-terminal structure and arginine acid at residue 3. Hence, it is named IGF-1 Long R3.⁽³⁾ Owing to the altered structure, Receptor Grade IGF-1 LR3 has been suggested to bind poorly with IGF-binding proteins, shortening its duration of action.

Overview

IGF proteins appear to exert potential via binding with IGF-1 receptors; however, researchers posit that these IGF binding proteins, including Receptor Grade IGF-1 LR3, may function either via IGF receptor-dependent mechanism or via IGF-independent mechanisms.⁽¹⁾⁽⁴⁾

A study⁽¹⁾ was conducted where a murine model was exposed to the endogenous IGF-1 with IGF-1 LR3. During this study, it was suggested that upon exposure, the synthetic protein exhibited the potential to quickly clear the serum and distribute into tissues. Increased concentrations of the IGF-1 LR3 tracer were apparently detected in specific organs, including the kidneys, ovaries, and adrenal glands, in mouse models. This distribution pattern indicates that organs critical to metabolism and reproductive processes might have differing abilities to absorb or retain IGF-1 LR3 compared to IGF-I. It is proposed that these variations might arise due to IGF-1 LR3's reduced tendency to bind with IGFBPs. IGFBPs are proteins that regulate the availability of IGFs in circulation, influencing their interaction with various tissues. The decreased binding of IGF-1 LR3 to IGFBPs may affect its bioavailability and interactions with specific tissues in research settings. Researchers suggest Receptor Grade IGF-1 LR3 has the potential to induce a signaling mechanism in the organism, either via autocrine mode (where the tissue cell stimulates itself) or via paracrine mode (where the tissue cell stimulates the nearby cell). The increased potential bioavailability of these autocrine and paracrine IGF-1 LR3 proteins may prove vital to inducing any possible action.

Chemical Makeup

Molecular Formula: C₄₀₀H₆₂₅N₁₁₁O_115S9
Molecular Weight: 9117.5 g/mol
Other known titles: Long-(arg3) insulin-like growth factor-I, Insulin-like growth factor long chain R3

Research and Clinical Studies

Receptor Grade IGF-1 LR3 Peptide and Tissue Anabolism

The body of research examining the anabolic capabilities of IGF-1 LR3 remains insufficient, primarily because this peptide is designed for evaluation in cell culture studies. However, limited studies using murine models hint at a considerable anabolic potential of IGF-1 LR3. In particular, one investigation involved normal and dexamethasone-induced catabolic murine models.⁽³⁾ The researchers commented that “LR3IGF-I, were approx. 2.5-fold more potent than IGF-I” in promoting anabolic observations. These included weight gain, increased weight of visceral organs, and potentially improved feed efficiency when the murine models were exposed to it continuously.

Another observation from studies on murine models exposed to catabolic agents revealed a reduction in the excretion of Nτ-methylhistidine, a marker of muscle protein degradation, which was notably more pronounced with IGF-1 LR3—potentially three times greater than with IGF-I. These observations indicate that IGF-1 LR3 may exhibit superior anabolic actions under specific experimental conditions, although this is not uniformly seen across all measured parameters. Therefore, it is conceivable that Receptor Grade IGF-1 LR3 may manifest an even greater anabolic capacity than IGF-1, according to multiple comparative studies on the anabolic properties of IGF-1.

For example, there is a 2005 clinical study⁽⁶⁾ where the action of rhIGF-1 on models of IGF-1 deficiency and growth disorders was studied. RhIGF-1 is the recombinant form of insulin-like growth factor-1, and has been researched for its potential in mitigating growth hormone (GH) insensitivity. RhIGF-1 is a synthetic form of IGF-1.⁽¹¹⁾ Research models of GH deficiencies were examined in the course of this controlled study, where rhIGF-1 was presented once daily to all the models. The heights and lengths were measured before and after the study. Researchers suggested that results indicated an average increase in height by 7cm per year in all subjects presented with rhIGF-1. Hence, this study posits that IGF-1 analogs may have a positive potential within the context of growth hormone deficiency research.

Receptor Grade IGF-1 LR3 and Metabolic Activity

Studies⁽⁷⁾ have suggested that IGF-binding proteins, including Receptor Grade IGF-1 LR3, may have the potential to induce glucose uptake and, thereby, glucose metabolism through the possible activation of signaling mechanisms. Namely, this may have occurred through a signaling mechanism involving PI3K and AMPK pathways. For example, it can be hypothesized that upon binding to their respective receptors, IGF-1 analogs potentially trigger a cascade of biochemical events involving the PI3K pathway. This pathway, integral to cellular growth and survival, might also play a pivotal role in mediating the actions of IGF-1 on glucose uptake. Activation of PI3K might lead to the stimulation of protein kinase B (Akt), a key regulator in the pathway, enhancing glucose transporter translocation to the cell membrane and increasing glucose uptake. Concurrently, the AMPK pathway, studied for its potential in energy balance and metabolism regulation, may be indirectly influenced by IGF-1 analogs. It is conceivable that the modulation of AMPK activity by these analogs may enhance cellular glucose uptake under energy stress conditions. This activation potentially promotes the translocation of GLUT4, a major glucose transporter, to the cell surface, thus facilitating glucose entry into cells.

Receptor Grade IGF-1 LR3 and Muscle

This study⁽⁸⁾ was conducted on female mice to examine the action of Receptor Grade IGF-1 LR3 on reducing myostatin. Myostatin is a muscle protein that primarily prevents muscle cell differentiation and growth. Reducing the action of myostatin may potentially increase lean muscle mass and reduce fat mass. In this study⁽⁸⁾ it was suggested that different IGF-1 analogs, including IGF-1 LR3, have the potential to counteract the negative action of myostatin protein, possibly helping to prevent apoptosis and protecting muscle cells. Since Receptor Grade IGF-1 LR3 has an apparently longer half-life than IGF-1 (according to the researchers), the potential action of Receptor Grade IGF-1 LR3 was considered.

Receptor Grade IGF-1 LR3 peptide is available for research and laboratory purposes only. Please review and adhere to our Terms and Conditions before ordering.

References:

1. Yakar, S et al., 40 YEARS OF IGF1: Insulin-like growth factors: actions on the skeleton (Jul 2018). Journal of Molecular Endocrinology, vol. 61 Issue 1. https://doi.org/10.1530/JME-17-0298
2. Growth hormone, athletic performance, and aging. Harvard Health Publishing, Harvard Medical School. https://www.health.harvard.edu/diseases-and-conditions/growth-hormone-athletic-performance-and-aging
3. Tomas, F. M., Knowles, S. E., Owens, P. C., Chandler, C. S., Francis, G. L., Read, L. C., & Ballard, F. J. (1992). Insulin-like growth factor-I (IGF-I) and especially IGF-I variants are anabolic in dexamethasone-treated rats. The Biochemical journal, 282 ( Pt 1)(Pt 1), 91–97. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1130894/
4. Mohan S, Baylink DJ. IGF-binding proteins are multifunctional and act via IGF-dependent and -independent mechanisms. J Endocrinol. 2002 Oct;175(1):19-31. https://pubmed.ncbi.nlm.nih.gov/12379487/
5. Anderson, L. J., Tamayose, J. M., & Garcia, J. M. (2018). Use of growth hormone, IGF-I, and insulin for anabolic purpose: Pharmacological basis, methods of detection, and adverse effects. Molecular and cellular endocrinology, 464, 65–74. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5723243/
6. IGF1 Deficiency, Recombinant Human Insulin-Like Growth Factor (rhIGF-1) Treatment of Short Stature Associated with IGF-1 Deficiency. https://clinicaltrials.gov/ct2/show/NCT00125190?cond=IGF1+Deficiency
7. Assefa, B., Mahmoud, A. M., Pfeiffer, A., Birkenfeld, A. L., Spranger, J., & Arafat, A. M. (2017). Insulin-Like Growth Factor (IGF) Binding Protein-2, Independently of IGF-1, Induces GLUT-4 Translocation and Glucose Uptake in 3T3-L1 Adipocytes. Oxidative medicine and cellular longevity, 2017 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5750484/
8. Naisi Li, Qiyuan Yang, Ryan G. Walker, Thomas B. Thompson, Min Du, Buel D. Rodgers, Myostatin Attenuation In Vivo Reduces Adiposity, but Activates Adipogenesis, Endocrinology, Volume 157, Issue 1, 1 January 2016, Pages 282–291. https://doi.org/10.1210/en.2015-1546
9. William E. Sonntag, Anna Csiszar, Raphael de Cabo, Luigi Ferrucci, Zoltan Ungvari, Diverse Roles of Growth Hormone and Insulin-Like Growth Factor-1 in Mammalian Aging: Progress and Controversies, The Journals of Gerontology: Series A, Volume 67A, Issue 6, June 2012, Pages 587–598, https://doi.org/10.1093/gerona/gls115
10. Mario Thevis (13 December 2010). Mass Spectrometry in Sports Drug Testing: Characterization of Prohibited Substances and Doping Control Analytical Assays. John Wiley & Sons. pp. 252. https://books.google.ca/books?id=dWHQMev5mHwC&pg=PA252&
11. Rosenbloom AL. Mecasermin (recombinant human insulin-like growth factor I). Ad Ther. 2009 Jan; 26(1):40-54. https://pubmed.ncbi.nlm.nih.gov/19198769/